KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Edwards Lifesciences (EW) over the last 17 years, with Q3 2025 value amounting to -$594.2 million.

  • Edwards Lifesciences' Net Cash Flow fell 12861.13% to -$594.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$991.3 million, marking a year-over-year decrease of 14337.72%. This contributed to the annual value of $1.9 billion for FY2024, which is 42208.59% up from last year.
  • Per Edwards Lifesciences' latest filing, its Net Cash Flow stood at -$594.2 million for Q3 2025, which was down 12861.13% from $170.8 million recorded in Q2 2025.
  • Over the past 5 years, Edwards Lifesciences' Net Cash Flow peaked at $2.1 billion during Q3 2024, and registered a low of -$675.6 million during Q4 2024.
  • In the last 5 years, Edwards Lifesciences' Net Cash Flow had a median value of $108.0 million in 2023 and averaged $76.5 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first crashed by 46089.35% in 2021, then surged by 82779.22% in 2023.
  • Edwards Lifesciences' Net Cash Flow (Quarter) stood at -$654.3 million in 2021, then increased by 29.56% to -$460.9 million in 2022, then surged by 43.05% to -$262.5 million in 2023, then crashed by 157.37% to -$675.6 million in 2024, then increased by 12.05% to -$594.2 million in 2025.
  • Its Net Cash Flow stands at -$594.2 million for Q3 2025, versus $170.8 million for Q2 2025 and $107.7 million for Q1 2025.